NICE

News

Sanofi's type 1 diabetes-delaying drug cleared for NHS use

People with early type 1 diabetes in England and Wales will soon be able to access Sanofi's Tzield, which can delay the need for insulin injections.

News

AbbVie's migraine drug cleared for migraine attacks on NHS

AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.

News

AbbVie's ovarian cancer drug Elahere gets NHS green light

AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.

News

NICE changes stance on Genmab's cervical cancer drug

After saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement authority NICE has had a change of heart.

News

NICE backs stomach cancer, PAH drugs for NHS use

AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.

News

Two hands pointing to each other index finger to index finger in a Chinese puzzle, on dark blue background

Joint MHRA/NICE pathway 'benefits industry over patients'

LSE pharma policy expert contends the MHRA/NICE aligned pathway is weighted towards industry, and calls for an assessment of its impact on the NHS.

Sanofi's type 1 diabetes-delaying drug cleared for NHS use

AbbVie's migraine drug cleared for migraine attacks on NHS

AbbVie's ovarian cancer drug Elahere gets NHS green light

NICE changes stance on Genmab's cervical cancer drug

NICE backs stomach cancer, PAH drugs for NHS use

Joint MHRA/NICE pathway 'benefits industry over patients'

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

NICE

Editor's Picks